Search results
Results From The WOW.Com Content Network
During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.
List of largest biomedical companies by revenue. The following is a list of independent pharmaceutical, biotechnology and medical companies listed on a stock exchange (as indicated) that have generated a revenue of at least US$ 10 billion, ranked by their revenue in the respective financial year. It does not include biotechnology companies that ...
As a small biotech with little revenue, no profits and no products on the market, stem cell therapy developer Athersys (NAS: ATHX) is particularly vulnerable to big drops in its share price. That ...
Based on our hedge fund sentiment data, we present to you, the 12 Best Large Biotech Stocks to Buy Now among the 800+ hedge funds by Insider Monkey: 12. Sarepta Therapeutics, Inc. (NASDAQ: SRPT ...
NASDAQ Biotechnology Index. The NASDAQ Biotechnology Index is a stock market index made up of securities of NASDAQ -listed companies classified according to the Industry Classification Benchmark as either the Biotechnology or the Pharmaceutical industry. [1] A list of the 225 components of the index is published online .
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Access Industries, Inc. is an United States-based [1] privately held multinational industrial group. [2] It was founded in 1986 by businessman Leonard "Len" Blavatnik. Access Industries' focus is in seven sectors: [3] biotechnology, entertainment, external funds, global media, strategic equity, technology ventures, and real estate.
While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.